Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot O60931: Variant p.Arg151Gly

Cystinosin
Gene: CTNS
Feedback?
Variant information Variant position: help 151 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Arginine (R) to Glycine (G) at position 151 (R151G, p.Arg151Gly). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from large size and basic (R) to glycine (G) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CTNS. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 151 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 367 The length of the canonical sequence.
Location on the sequence: help GWIYFVAWSISFYPQVIMNW R RKSVIGLSFDFVALNLTGFV The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GWIYFVAWSISFYPQVIMNWRRKSVIGLSFDFVALNLTGFV

Mouse                         GWIYFMAWSVSFYPQVIQNWRRKSVIGLSFDFLALNLTGFV

Bovine                        GWIYFVAWSVSFYPQVITNWRRKSVVGLSFDFVVLNLMGFV

Caenorhabditis elegans        GWTYFFAWSISFYPQMYLNFKRKSVVGLNFDFLSLNLVGFC

Drosophila                    GWVYFVAWSVSFYPQIWSNYRRKSVEGLNFDFLALNIVGFT

Slime mold                    GWIYFACWSLSFYPQVILNFRKKNVIGLSFDFLLFNITGYA
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 23 – 367 Cystinosin
Topological domain 151 – 159 Cytoplasmic
Domain 123 – 189 PQ-loop 1
Binding site 166 – 166
Mutagenesis 131 – 131 G -> SD. Gain-of-function mutant that shows higher transport of cystine.
Mutagenesis 134 – 134 Y -> AF. Nearly abolished cystine transport.
Mutagenesis 137 – 137 A -> V. Gain-of-function mutant that shows higher transport of cystine.
Mutagenesis 138 – 138 W -> F. Abolished cystine transport.
Mutagenesis 142 – 142 F -> A. Abolished cystine transport.
Mutagenesis 143 – 143 Y -> F. Slightly decreased midpoint potential. Impaired dielectric distance.
Mutagenesis 145 – 145 Q -> A. Increased cystine uptake activity.
Mutagenesis 152 – 152 R -> Q. Impaired dielectric distance.
Mutagenesis 161 – 161 D -> N. Strongly reduced steady-state transport current. Slightly decreased midpoint potential.
Mutagenesis 166 – 166 N -> A. Abolished cystine transport.
Mutagenesis 170 – 170 F -> A. Strongly decreased cystine transport.
Helix 142 – 152



Literature citations
Genetic basis of cystinosis in Turkish patients: a single-center experience.
Topaloglu R.; Vilboux T.; Coskun T.; Ozaltin F.; Tinloy B.; Gunay-Aygun M.; Bakkaloglu A.; Besbas N.; van den Heuvel L.; Kleta R.; Gahl W.A.;
Pediatr. Nephrol. 27:115-121(2012)
Cited for: VARIANTS CTNS GLY-151; ASP-157 AND CYS-173;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.